Yi Shan Li
Fondateur chez Blossomhill Therapeutics, Inc.
Profil
Yi Shan Li is the founder of two companies.
Turning Point Therapeutics, Inc. is founded in 2013, and Blossomhill Therapeutics, Inc. is founded in 2020, where he currently holds the title of Executive Chairman.
Dr. Li's former jobs include Director at SABiosciences Corp.
from 2002 to 2009, Executive Vice President at Epitomics, Inc. from 2008 to 2013, and Principal at Santa Cruz Biotechnology, Inc. Dr. Li also held the title of Vice President at Kenson Ventures LLC from 2001 to 2003 and Principal at RBC Capital Markets LLC.
Dr. Li's education includes a doctorate from The Ohio State University in 1994, an MBA from the University of California, Berkeley in 2001, and an undergraduate degree from the University of Science & Technology of China in 1987.
Postes actifs de Yi Shan Li
| Sociétés | Poste | Début |
|---|---|---|
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Fondateur | 01/07/2020 |
Anciens postes connus de Yi Shan Li
| Sociétés | Poste | Fin |
|---|---|---|
| TURG POIN | Directeur Général | 01/09/2018 |
Epitomics, Inc.
 Epitomics, Inc. Pharmaceuticals: MajorHealth Technology Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. | Corporate Officer/Principal | 30/04/2013 |
SABiosciences Corp.
 SABiosciences Corp. Medical SpecialtiesHealth Technology SABiosciences Corp. develops and markets technologies for genetic and medical research. It is a biotechnology company that envisions a new and systematic approach to biological research in the post-genomic era. The company was founded in 1998 and is headquarterd in Frederick, MD. | Directeur/Membre du Conseil | 31/12/2009 |
Kenson Ventures LLC
 Kenson Ventures LLC Investment ManagersFinance Kenson Ventures LLC (Kenson Ventures) is a venture capital firm founded in 1999 by Kenneth Fong. The firm is headquartered in in Palo Alto, California. | Private Equity Investor | 31/12/2003 |
RBC Capital Markets LLC
 RBC Capital Markets LLC Investment Banks/BrokersFinance RBC Capital Markets LLC is a full-service brokerage and financial services firm headquartered in New York City. They are a direct subsidiary of RBC USA Holdco Corp. and a wholly-owned indirect subsidiary of Royal Bank of Canada (TSE, NYSE: RY). Founded in 2010, the firm is comprised of 3 major business lines: the Private Client Group, the Fixed-Income Group and the Clearing and Execution Services Group. The Private Client Group serves individual investors, while the Fixed-Income Group provides services to institutions, municipalities and non-profit organizations. The Clearing and Execution Services Group is a provider of clearing and execution services to independent brokers/dealers throughout the US. RBC Capital Markets focuses on the following sectors: communications, media, consumer/retail, diversified industries, energy, financial institutions, forest products, healthcare, infrastructure finance, mining & metals, real estate, social infrastructure, technology and the US municipal markets. | Corporate Officer/Principal | - |
Formation de Yi Shan Li
| The Ohio State University | Doctorate Degree |
| University of California, Berkeley | Masters Business Admin |
| University of Science & Technology of China | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Epitomics, Inc.
Epitomics, Inc. Pharmaceuticals: MajorHealth Technology Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
RBC Capital Markets LLC
RBC Capital Markets LLC Investment Banks/BrokersFinance RBC Capital Markets LLC is a full-service brokerage and financial services firm headquartered in New York City. They are a direct subsidiary of RBC USA Holdco Corp. and a wholly-owned indirect subsidiary of Royal Bank of Canada (TSE, NYSE: RY). Founded in 2010, the firm is comprised of 3 major business lines: the Private Client Group, the Fixed-Income Group and the Clearing and Execution Services Group. The Private Client Group serves individual investors, while the Fixed-Income Group provides services to institutions, municipalities and non-profit organizations. The Clearing and Execution Services Group is a provider of clearing and execution services to independent brokers/dealers throughout the US. RBC Capital Markets focuses on the following sectors: communications, media, consumer/retail, diversified industries, energy, financial institutions, forest products, healthcare, infrastructure finance, mining & metals, real estate, social infrastructure, technology and the US municipal markets. | Finance |
Kenson Ventures LLC
Kenson Ventures LLC Investment ManagersFinance Kenson Ventures LLC (Kenson Ventures) is a venture capital firm founded in 1999 by Kenneth Fong. The firm is headquartered in in Palo Alto, California. | Finance |
Santa Cruz Biotechnology, Inc.
 Santa Cruz Biotechnology, Inc. BiotechnologyHealth Technology Santa Cruz Biotechnology, Inc. provides antibodies & support products services. The firm's products include cell adhesion protein, growth factor, steroid receptor, and tumor suppressor antibodies. The company is headquartered in Santa Cruz, CA. | Health Technology |
SABiosciences Corp.
SABiosciences Corp. Medical SpecialtiesHealth Technology SABiosciences Corp. develops and markets technologies for genetic and medical research. It is a biotechnology company that envisions a new and systematic approach to biological research in the post-genomic era. The company was founded in 1998 and is headquarterd in Frederick, MD. | Health Technology |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation. | Health Technology |
